All posts

Take a pass on Celestica, says RBC Capital

Ahead of second quarter earnings from Celestica (Celestica Stock Quote, Chart, News TSX:CLS) analyst Paul Treiber of RBC Capital is sticking with his “Hold” rating on the stock.

Trieber issued an update on his coverage on Tuesday in which he set a target price of $7.50 per share, which is above analysts’ target consensus of $6.69.

Headquartered in Toronto, Celestica is an electronics manufacturing services company with an Advanced Technology Solutions (ATS) segment and Connectivity & Cloud Solutions (CCS) segment, the latter of which went through a review as part of a wider restructuring conducted by the company and featuring a disengagement from programs with Cisco Systems.

Celestica’s CCS segment saw its revenue drop last quarter due to demand softness from its communications customers, a state of affairs the company expects will continue into the second quarter, due on Wednesday July 29.

For its Q1 2020, Celestica reported total revenue down eight per cent year-over-year to $1.32 billion, with a five-per-cent drop in ATS revenue and a ten per cent decrease in CCS revenue. Adjusted earnings (non-IFRS) came in at $0.16 per share compared to $0.12 per share a year earlier. (All figures in US dollars except where noted otherwise.)

At the time, management spoke of the challenge currently being faced due to the COVID-19 pandemic, which has caused a decline in demand for Celestica’s products.

“While the full impact and duration of COVID-19 is unknown at this time, we believe Celestica’s swift response, diversification, improved operating model, and solid balance sheet position us well to weather this disruption. Despite the current challenges, our long-term goal to generate sustainable profitable growth remains unchanged,” said Rob Mionis, CEO and president, in a press release.

Year-to-date, Celestica’s share price is down 13 per cent. At press time, Trieber’s $7.50 target represented a projected 12-month return of 7.6 per cent.

Tagged with: cls
Jayson MacLean

Jayson is a writer, researcher and educator with a PhD in political philosophy from the University of Ottawa. His interests range from bioethics and innovations in the health sciences to governance, social justice and the history of ideas.

Recent Posts

This Canadian smallcap stockhas big potential, analyst says

In a Sept. 17 report, Haywood Capital Markets analyst Gianluca Tucci said a new memorandum of understanding signed by MineHub… [Read More]

10 hours ago

Quebecor wins price target raise at National Bank

National Bank Financial analyst Adam Shine raised his price target on Quebecor (Quebecor Stock Quote, Chart, News, Analysts, Financials TSE:QBR.B)… [Read More]

13 hours ago

Cipher Pharmaceuticals is about to ramp up, Stifel says

In a Sept. 16 note, Stifel analyst Justin Keywood reiterated a “Buy” rating and C$20.00 target on Cipher Pharmaceuticals (Cipher… [Read More]

14 hours ago

High Tide is building momentum, this analyst says

In a Sept. 15 note, Roth Capital Markets analyst Bill Kirk reiterated a “Buy” rating and $5.00 price target on… [Read More]

2 days ago

Rogers Communications named a “Best Idea” at TD Cowen

In its Canada Best Ideas 2025 report, TD Cowen analyst Vince Valentini reiterated his “Buy” rating on Rogers Communications (Rogers… [Read More]

2 days ago

Hut 8 wins massive price target raise at Roth

In a Sept. 15 report, Roth Capital Markets analyst Darren Aftahi reiterated a “Buy” rating on Hut 8 (Hut 8… [Read More]

3 days ago